Sol-Gel Technologies (SLGL) Short term Debt (2016 - 2017)
Sol-Gel Technologies' (SLGL) quarterly Short term Debt came in at $65.3 million in Q4 2017, up 74.99% year-on-year from $37.3 million in Q4 2016, and up 74.99% on a QoQ basis from $37.3 million in Q4 2016.
Sol-Gel Technologies (SLGL) Short term Debt (2016 - 2017) Analysis & Trends
Sol-Gel Technologies (SLGL) has 2 years of Short term Debt data on file, last reported at $65.3 million in Q4 2017.
- On a quarterly basis, Short term Debt rose 74.99% year-over-year to $65.3 million in Q4 2017; TTM through Dec 2017 was $65.3 million, a 74.99% increase from a year earlier, with the FY2017 full-year figure at $65.3 million, up 74.99% from the prior year.
- Short term Debt for Q4 2017 stood at $65.3 million, up from $37.3 million in the prior quarter.
- Over the last five years, Short term Debt for SLGL reached as high as $65.3 million in Q4 2017 and fell as low as $37.3 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Sol-Gel Technologies | 227.58 Mn | 217.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 65.34 Mn |
| Dec 31, 2016 | 37.34 Mn |